Transaction strengthens and broadens Pall offering for biopharmaceutical customers
ATMI is to sell its LifeSciences business to Pall Corporation, a filtration, separation and purification specialist, for US$185m.
The deal includes all assets associated with ATMI's LifeSciences business, including two locations in Belgium plus a shared facility in Minnesota, US.
ATMI, which specialises in single-use bioprocess systems and consumables for the pharma and biopharma industries, expects the transaction to close during the first quarter of this year, subject to regulatory approvals and customary closing conditions.
'We are very happy to have Pall as the new owner of this business, and believe the fit with Pall's capabilities will accelerate its growth and provide great customer support,' said ATMI's Chief Executive, Doug Neugold.
'This acquisition immediately strengthens our offering and broadens our already extensive portfolio of advanced solutions for biopharmaceutical customers,' added Larry Kingsley, Chairman and CEO of Pall.